Commercialized Active Pharmaceutical Ingredient
Product Name
CAS Number
Specification
TP
DMF
Status
Abemaciclib
1231929-97-7
In-house
Q4 2025
Alectinib
1256580-46-7
In-house
Q4 2025
Apixaban
503612-47-3
In-house
√
Asenapine
65576-45-6
In-house
√
Avatrombopag
570406-98-3
In-house
√
Benzoxonium chloride
19379-90-9
In-house
√
Bicyclol
118159-48-1
CP, In-house
√
Bimatoprost
155206-00-1
In-house
Q3 2025
Binimetinib
606143-89-9
In-house
Q4 2025
Cabozantinib
849217-68-1
In-house
Q4 2025
Calcium Saccharate
5793-89-5
CP, In-house
Dabrafenib mesylate
1195768-06-9
In-house
Q4 2025
Dapagliflozin
461432-26-8
USP, In-house
Efinaconazole
164650-44-6
In-house
√
Eliglustat Tartrate
928659-70-5
In-house
√
Entecavir Monohydrate
209216-23-9
USP, EP, in-house
√
Febuxostat
144060-53-7
In-house
√
Fluvastatin sodium
93957-55-2
CP, USP, EP, JP
√
Galanthamine
357-70-0
EP, In-house
Q3 2025
Imatinib Mesylate
220127-57-1
EP, In-house
√